X0306 4 2019-05-09 1 0001563880 Trevi Therapeutics, Inc. TRVI 0001659119 Aperture Venture Partners IV, L.P. 645 MADISON AVENUE, 20TH FLOOR NEW YORK NY 10022 0 0 1 0 0001775271 Aperture Ventures IV Management, LLC 645 MADISON AVENUE, 20TH FLOOR NEW YORK NY 10022 0 0 1 0 Common Stock 2019-05-09 4 C 0 232963 A 232963 D Common Stock 2019-05-09 4 P 0 112000 10.00 A 344963 D Series C Preferred Stock 2019-05-09 4 C 0 2054795 0.00 D Common Stock 232963 0 D On May 9, 2019, the Series C Preferred Stock, and the dividends that had accrued thereon to date, converted into Common Stock on a 9.5-for-one basis without payment of further consideration automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date. Aperture Ventures IV Management, LLC, the general partner of Aperture Venture Partners IV, L.P., has sole voting and investment control with respect to shares of the Issuer's common stock held by Aperture Venture Partners IV, L.P. By: Aperture Venture Partners IV, L.P., By: Aperture Ventures IV Management, LLC, /s/ Eric Sillman, Member 2019-05-09 By: Aperture Ventures IV Management, LLC, /s/ Eric Sillman, Member 2019-05-09